Patents Assigned to School Corporation, Azabu Veterinary Medicine Educational Institution
-
Publication number: 20240390472Abstract: It is an object of the present invention to provide a vaccine effective for protection against infection by Streptococcus species that causes mastitis in livestock and other animals. Specifically, the present invention provides a vaccine comprising a non-encapsulated strain of Streptococcus species as an antigen, and in particular, a vaccine for preventing mastitis developed by infection by Streptococcus uberis.Type: ApplicationFiled: September 20, 2022Publication date: November 28, 2024Applicants: NATIONAL AGRICULTURE AND FOOD RESEARCH ORGANIZATION, SCHOOL CORPORATION, AZABU VETERINARY MEDICINE EDUCATIONAL INSTITUTIONInventors: Atsushi WATANABE, Eiji HATA, Shinya GOTO, Kazuhiro KAWAI
-
Publication number: 20240180990Abstract: Methane production from ruminant digestion is reduced by allowing a ruminant to be fed on feed containing unfermented coffee grounds.Type: ApplicationFiled: April 7, 2022Publication date: June 6, 2024Applicants: TOKUYAMA CORPORATION, SCHOOL CORPORATION, AZABU VETERINARY MEDICINE EDUCATIONAL INSTITUTIONInventors: Kie YAMADA, Yoji INUI, Kazuhiro KAWAI, Tomomi KURUMISAWA
-
Publication number: 20240000858Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.Type: ApplicationFiled: December 20, 2022Publication date: January 4, 2024Applicants: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational InstitutionInventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
-
Patent number: 11826424Abstract: Strains of human-derived bacteria have been obtained from complex fecal samples and shown to induce accumulation of Th17 cells in the intestine and promote immune functions. Pharmaceutical compositions containing these bacteria can be used as anti-infectives and as adjuvants in mucosal vaccines.Type: GrantFiled: May 14, 2021Date of Patent: November 28, 2023Assignees: RIKEN, The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational InstitutionInventors: Kenya Honda, Koji Atarashi, Masahira Hattori, Hidetoshi Morita
-
Publication number: 20230213511Abstract: There are provided a method and a kit for evaluating allergen inactivators, the method and kit making it possible to carry out a precise and reproducible evaluation irrespective of the type of test drug, or the type of accompanying components thereof, that is subject to the evaluation.Type: ApplicationFiled: April 23, 2021Publication date: July 6, 2023Applicants: SCHOOL CORPORATION, AZABU VETERINARY MEDICINE EDUCATIONAL INSTITUTION, ITEA INCInventors: Masahiro SAKAGUCHI, Jumpei UCHIYAMA, Megumi YOSHIDA, Keijiro MIZUKAMI, Keigo MIZUKAMI, Keigo KURATA
-
Publication number: 20230119232Abstract: The present invention is intended to provide a lactic acid bacterium-containing composition that is effective for suppression of the onset of allergies. More specifically, the present invention relates to a composition comprising lactic acid bacteria belonging to Lactobacillus animalis, wherein the composition is provided in the form of, for example, a food or beverage composition, a pharmaceutical composition, a feed composition, a sanitary composition or the like. Furthermore, the present invention provides a method for preventing the onset of allergies.Type: ApplicationFiled: March 5, 2021Publication date: April 20, 2023Applicants: SCHOOL CORPORATION, AZABU VETERINARY MEDICINE EDUCATIONAL INSTITUTION, ITEA INC.Inventors: Masahiro SAKAGUCHI, Jumpei UCHIYAMA, Tomoki FUKUYAMA
-
Patent number: 11547732Abstract: Provided herein are methods of treating graft-versus-host disease in a subject by administering pharmaceutical compositions containing bacterial strains of the Clostridia class. Also described herein are exemplary human-derived bacteria belonging to the Clostridia class, combinations of which have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions, and are therefore useful for mitigating pathological immune responses. Pharmaceutical compositions containing these and/or related bacteria can be used to prevent and treat immune-mediated diseases such as graft-versus-host disease.Type: GrantFiled: October 15, 2020Date of Patent: January 10, 2023Assignees: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational InstitutionInventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
-
Publication number: 20220072125Abstract: Strains of human-derived bacteria have been obtained from complex fecal samples and shown to induce accumulation of Th17 cells in the intestine and promote immune functions. Pharmaceutical compositions containing these bacteria can be used as anti-infectives and as adjuvants in mucosal vaccines.Type: ApplicationFiled: May 14, 2021Publication date: March 10, 2022Applicants: RIKEN, The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational InstitutionInventors: Kenya Honda, Koji Atarashi, Masahira Hattori, Hidetoshi Morita
-
Publication number: 20210393660Abstract: There is provided with a method of treating cancer. A set of administration of a compound represented by General Formula (I) or a pharmaceutically acceptable salt thereof to a patient, at a dose such that 8 mg/kg or less of the compound represented by General Formula (I) is administered, and irradiation to the patient immediately following the administration is repeated. A total dosage of the irradiation to a cancer is 10 Gy or more.Type: ApplicationFiled: September 3, 2021Publication date: December 23, 2021Applicants: M.T.3, Inc., NIHON UNIVERSITY, SCHOOL CORPORATION, AZABU VETERINARY MEDICINE EDUCATIONAL INSTITUTIONInventors: Hiroeki SAHARA, Tomohiro NAKAYAMA, Takuya MARUO
-
Publication number: 20210386783Abstract: The prevent invention provides an activated T cell in which the expression of an immune checkpoint molecule is suppressed, a method for producing the T cell, and a method for screening for a substance that can be used in the production of the T cell. Specifically, the prevent invention includes, as solving means, a method for producing or inducing a T cell in which the expression of an immune checkpoint molecule is not induced, the method comprising reducing or losing the function of UDP-glucose ceramide glucosyltransferase (UGCG) or ganglioside in a T cell, and a T cell produced or induced by the aforementioned method.Type: ApplicationFiled: October 24, 2019Publication date: December 16, 2021Applicants: SCHOOL CORPORATION, AZABU VETERINARY MEDICINE EDUCATIONAL INSTITUTION, TELLA, INC.Inventors: Tadashi YAMASHITA, Masaki NAGANE, Teruo IKEDA, Shoichiro MIYATAKE, Mariko OKAMOTO
-
Publication number: 20210137998Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.Type: ApplicationFiled: October 15, 2020Publication date: May 13, 2021Applicants: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational InstitutionInventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
-
Patent number: 10835559Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.Type: GrantFiled: October 25, 2018Date of Patent: November 17, 2020Assignees: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational InstitutionInventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
-
Patent number: 10624933Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.Type: GrantFiled: May 31, 2019Date of Patent: April 21, 2020Assignees: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational InstitutionInventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
-
Publication number: 20190314426Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.Type: ApplicationFiled: May 31, 2019Publication date: October 17, 2019Applicants: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational InstitutionInventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
-
Publication number: 20190290753Abstract: Strains of human-derived bacteria have been obtained from complex fecal samples and shown to induce accumulation of Th17 cells in the intestine and promote immune functions. Pharmaceutical compositions containing these bacteria can be used as anti-infectives and as adjuvants in mucosal vaccines.Type: ApplicationFiled: April 5, 2019Publication date: September 26, 2019Applicants: Riken, The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational InstitutionInventors: Kenya Honda, Koji Atarashi, Masahira Hattori, Hidetoshi Morita
-
Patent number: 10342832Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.Type: GrantFiled: October 15, 2018Date of Patent: July 9, 2019Assignees: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational InstitutionInventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
-
Patent number: 10300137Abstract: Strains of human-derived bacteria have been obtained from complex fecal samples and shown to induce accumulation of Th17 cells in the intestine and promote immune functions. Pharmaceutical compositions containing these bacteria can be used as anti-infectives and as adjuvants in mucosal vaccines.Type: GrantFiled: April 10, 2015Date of Patent: May 28, 2019Assignees: RIKEN, The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational InstitutionInventors: Kenya Honda, Koji Atarashi, Masahira Hattori, Hidetoshi Morita
-
Patent number: 10238694Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.Type: GrantFiled: November 29, 2012Date of Patent: March 26, 2019Assignees: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational InstitutionInventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
-
Publication number: 20190046591Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.Type: ApplicationFiled: October 25, 2018Publication date: February 14, 2019Applicants: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational InstitutionInventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
-
Publication number: 20190030092Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.Type: ApplicationFiled: October 15, 2018Publication date: January 31, 2019Applicants: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational InstitutionInventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita